Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Liquid Biopsy Assays Sensitive for NSCLC EGFR Mutations
Key clinical point: In patients with NSCLC, EGFR mutation testing by ddPCR or NGS using plasma-derived cell-free DNA performs similarly to NGS testing using tissue.
Major finding: There was high agreement between liquid biopsy methods (86%-94%) and generally good concordance with NGS tissue results (69%-83%).
Study details: Retrospective cohort study of 36 patients with EGFR-mutated NSCLC experiencing progression on their current therapy.
Disclosures: Dr. Steendam disclosed that she receives research funding from AstraZeneca (institutional) and travel, accommodations, and/or expenses from Roche, Boehringer Ingelheim, and Eli Lilly. The study did not receive any specific funding.
Steendam CMJ et al. JCO Precis Oncol. 2019 June 20. doi: 10.1200/PO.18.00401.